Panacea Biotech Falls After Adar Poonawalla Offloads Stake For Rs 118 Crore
Panacea Biotech Share Price: On Tuesday, Panacea Biotech opened on the BSE at Rs 389, swinging to anan intra day high of Rs 393.15 and an intra day low of Rs 372.50, so far.
Panacea Biotec Ltd - 531349 - Intimation Of Suit Filed By Panacea Biotec Limited ('Company') Against Sanofi Healthcare India Private Limited
We would like to inform you that the Company has instituted a suit before the Hon'ble Delhi High Court seeking to restrain Sanofi Healthcare India Private Limited from marketing a fully liquid hexavalent vaccine that would infringe Company's patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySixTM. Panacea Biotec's EasySixTM is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySixTM has been in the market since 2017. A brief note in respect of the above mentioned matter is enclosed herewith for your kind information and record please. Kindly acknowledge the receipt.
Panacea Biotech up 5% after govt proposes to ramp up production of COVAXIN
Panacea Biotech has Biosafety level 3 or BSL-3 which is equipped to safely handle infectious biological pathogens in the highest stringent environmentally controlled manufacturing facility. Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, the details of shares dematerialized during April, 2021 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 are enclosed herewith. PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt Ltd PANACEA BIOTEC LTD. - 531349 - Clarification On Movement In Price
With reference to the captioned subject, we would like to state as under: 1. The Company has made all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from time to time and has not withheld any material information/ announcement that in our opinion would have a bearing on the price / volume behavior in the scrip. 2. As on date, there are no pending information/ announcement (including impending announcement) which in our opinion may have a bearing on the price / volume behavior in the scrip. You are requested to take the same on records. Panacea Biotec Ltd - 531349 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half-Year Ended March 31, 2021
Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certified copy of certificate from M/s. R & D, Company Secretaries, for the half-year ended March 31, 2021, confirming that all the transfers of shares have been completed within the stipulated time.
Pharma stocks scale fresh highs amid record rise in Covid-19 cases
Shares of Panacea Biotech were locked in the 10 per cent upper circuit for the second straight day, at Rs 323.70, hitting an over 12-year high on the BSE on Thursday Panacea Biotec Ltd - 531349 - Shareholding for the Period Ended March 31, 2021
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Panacea Biotec Ltd - 531349 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half Year Ended On March 31, 2021
Pursuant to the provisions of Regulation 7(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certificate duly signed by Skyline Financial Services Pvt. Ltd., Share Transfer Agent and Company Secretary of Panacea Biotec Ltd. for the half year ended on March 31, 2021 in compliance of Regulation 7(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.